Patients with Stage B asymptomatic heart failure (HF) have a higher risk of premature mortality. Obesity also represents an independent risk factor for developing HF and is independently associated with poorer clinical outcomes. We aimed to characterize the clinical status, inflammatory biomarkers and health-related behaviors in stage B HF patients with normal weight, overweight, and obesity.
This was a cross-sectional analysis of a cohort of HF patients. Weight classification was set as normal weight (BMI ≤ 24.9), overweight (25–29.9) and obesity (≥ 30). ANOVAs and Chi-Square tests were used for comparisons, and Pearson’s correlations explored the relationships of inflammation biomarkers and BMI. Significance was set at p≤ 0.05.
Of 356 patients, 59 patients had normal weight (BMI 22.9 [2.0]), 120 had overweight (27.7 [1.4]), and 177 had obesity (34.3 [4.9]). The prevalence of diabetes type 2 (p<0.001), hypertension (p<0.001), LV hypertrophy (p=0.04) and the use of diuretics (p=0.036) were significantly higher in the overweight and obesity groups. Patients with overweight/obesity were less active (p=0.04), had poorer sleep (p=0.02), perceived worse quality of life related to physical functioning (p=0.001), vitality (p=0.02), bodily pain (p=0.01) and general health (p= 0.012). Inflammatory biomarkers were not significantly different between groups, but non-fasting glucose and C-reactive protein were positively correlated with higher BMI (r= .151, p= 0.23 and r=.110, p=.040, respectively).
In our cohort, HF patients with overweight and obesity experienced worse heart-related clinical status. Higher BMIs were also associated with less physical activity, poorer sleep, and overall worse quality of life in these HF patients.